SCHEMBL16516649

SCHEMBL16516649

COc1cc(OCc2ccc(Cl)cc2)ccc1/C=C/C(=O)NO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 8/20 0.72
▸ MAPT P10636 4/20 0.55
▸ LMNA P02545 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ LY96 Q9Y6Y9 1/20 0.54
▸ HDAC1 Q13547 4/20 0.50
▸ HDAC6 Q9UBN7 3/20 0.50
▸ HDAC3 O15379 2/20 0.50
▸ HDAC2 Q92769 2/20 0.50
▸ BACE1 P56817 1/20 0.50
▸ HDAC4 P56524 1/20 0.50
▸ HDAC7 Q8WUI4 1/20 0.50
▸ HDAC10 Q969S8 1/20 0.50
▸ HDAC11 Q96DB2 1/20 0.50
▸ HDAC9 Q9UKV0 1/20 0.50
▸ HDAC5 Q9UQL6 1/20 0.50
▸ APP P05067 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16516442 0.92 HDAC8 (0.84) HDAC8MAPTLY96HDAC1HDAC6
SCHEMBL16516670 0.91 HDAC8 (0.87) HDAC8MAPTLMNAHPGDLY96
SCHEMBL16516641 0.90 HDAC8 (0.73) HDAC8MAPTLY96HDAC1HDAC6
SCHEMBL18538449 0.89 HDAC8 (0.71) HDAC8MAPTLY96HDAC1HDAC3
SCHEMBL16516744 0.84 HDAC8 (1.00) HDAC8MAPTLY96HDAC1HDAC6
SCHEMBL16516237 0.81 HDAC8 (0.89) HDAC8MAPTLY96HDAC1HDAC6
SCHEMBL18542270 0.80 LY96 (0.74) HDAC8MAPTLY96HDAC1HDAC6
SCHEMBL16516560 0.80 HDAC8 (0.87) HDAC8MAPTLY96HDAC1HDAC3
SCHEMBL31533148 0.80 ALDH1A1 (0.58) MAPTLMNAHPGDAPPNPC1
SCHEMBL7780908 0.77 HDAC8 (0.51) HDAC8MAPTLMNAHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190322617-A1 HDAC8 INHIBITORS FOR TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-24 — — US disclosed
US-10308596-B2 HDAC8 inhibitors for treating cancer CITY OF HOPE (US) 2019-06-04 — — US disclosed
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER CITY OF HOPE 2017-02-23 — — US disclosed
EP-3035924-A2 HDAC8 INHIBITORS FOR TREATING CANCER City of Hope (US) 2016-06-29 — — EP disclosed
WO-2015026935-A2 HDAC8 INHIBITORS FOR TREATING CANCER CITY OF HOPE (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER HDAC8, HDAC1, HDAC7 HDAC8 1/4885MAPT 3015/4885LMNA 1658/4885
US-10308596-B2 HDAC8 inhibitors for treating cancer HDAC8, HDAC1, HDAC7 HDAC8 1/4885MAPT 3015/4885LMNA 1658/4885
US-20190322617-A1 HDAC8 INHIBITORS FOR TREATING CANCER HDAC8, HDAC1, HDAC7 HDAC8 1/4885MAPT 3015/4885LMNA 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback